Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m. Valerie Vanhooren (Ona Therapeutics) Benefitting from the heat surrounding the space, Ona Therapeutics has raised a sizeable amount of cash to advance its pipeline of first-in-class antibody-drug conjugates (ADCs).